US 12,296,002 B2
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Tsun-Yung Kuo, I-Lan County (TW); Charles Chen, Taipei (TW); Chung-Chin Wu, I-Lan County (TW); Yi-Jiun Lin, Taipei (TW); Meei-Yun Lin, Taipei (TW); Yu-Chi Wu, Taipei (TW); John Darren Campbell, Emeryville, CA (US); Robert S. Janssen, Emeryville, CA (US); David Novack, Emeryville, CA (US); Robert Coffman, Emeryville, CA (US); and Paula Traquina, Emeryville, CA (US)
Assigned to MEDIGEN VACCINE BIOLOGICS CORPORATION, Zhubei (TW); and DYNAVAX TECHNOLOGIES CORPORATION, Emeryville, CA (US)
Filed by Medigen Vaccine Biologics Corporation, Zhubei (TW); and Dynavax Technologies Corporation, Emeryville, CA (US)
Filed on Jun. 18, 2021, as Appl. No. 17/351,363.
Application 17/351,363 is a continuation of application No. PCT/US2021/020277, filed on Mar. 1, 2021.
Claims priority of provisional application 63/040,696, filed on Jun. 18, 2020.
Claims priority of provisional application 62/983,737, filed on Mar. 1, 2020.
Prior Publication US 2021/0308257 A1, Oct. 7, 2021
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); C07K 14/005 (2006.01); C07K 14/165 (2006.01); C07K 14/245 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); C07K 14/005 (2013.01); C07K 14/165 (2013.01); C07K 14/245 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/575 (2013.01); C07K 2319/33 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/20071 (2013.01); C12N 2795/10022 (2013.01); C12N 2795/10034 (2013.01); C12N 2795/10071 (2013.01)] 14 Claims
OG exemplary drawing
 
1. An immunogenic composition against a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising an antigenic recombinant protein and an adjuvant consisting of aluminum hydroxide and an unmethylated cytosine-phosphate-guanosine (CpG) motif consisting of a synthetic oligodeoxynucleotide (ODN) of SEQ ID NO: 8, wherein the antigenic recombinant protein substantially consists of residues 14-1208 of SARS-CoV-2 S protein with proline substitutions at residues 986 and 987 and a “GSAS” substitution at residues 682-685 and a C-terminal T4 fibritin trimerization domain consisting of an amino acid sequence of SEQ ID NO: 2.